About Tirzepatide
Tirzepatide is a dual GIP and GLP-1 receptor agonist used in metabolic research. Supplied as a lyophilized powder for laboratory studies investigating dual incretin receptor activation, insulin-related signaling pathways, and glucose homeostasis mechanisms in controlled experimental models. Each batch undergoes analytical verification for identity and purity using HPLC and mass spectrometry. Supplied as: Lyophilized powder Purity: >95-99 (HPLC verified) Storage: Store desiccated at ?20�C for long-term. Short-term room temperature exposure (around 1 month) during shipping/handling is generally acceptable if kept sealed, dry, and protected from heat/light. Designation: FOR RESEARCH USE ONLY. Not intended for human or animal consumption.
Latest Research
Enhancing economic modelling in obesity: integrating novel type 2 diabetes progression & obstructive sleep apnea remission - a UK case study.
Recent research on Tirzepatide: Enhancing economic modelling in obesity: integrating novel type 2 diabetes progression & obstructive sleep apnea remission - a UK case study.
Read Full Study on PubMedReal-world treatment satisfaction and experience with once-weekly tirzepatide: Insights from prescribing physicians and people with obesity or overweight.
Recent research on Tirzepatide: Real-world treatment satisfaction and experience with once-weekly tirzepatide: Insights from prescribing physicians and people with obesity or overweight.
Read Full Study on PubMedAdditional Studies
Personalization of incretin therapy: can GLP-1 and GIP receptor polymorphisms influence therapy response?
Recent research on Tirzepatide: Personalization of incretin therapy: can GLP-1 and GIP receptor polymorphisms influence therapy response?
Read on PubMedPapular granuloma annulare associated with tirzepatide: A case report.
Recent research on Tirzepatide: Papular granuloma annulare associated with tirzepatide: A case report.
Read on PubMedImpact of incretin therapies on biochemical and imaging outcomes in metabolic dysfunction-associated steatotic liver disease.
Recent research on Tirzepatide: Impact of incretin therapies on biochemical and imaging outcomes in metabolic dysfunction-associated steatotic liver disease.
Read on PubMedTirzepatide-Induced Weight Loss and Exacerbation of Bipolar Disorder With Clozapine Treatment: A Case Report.
Recent research on Tirzepatide: Tirzepatide-Induced Weight Loss and Exacerbation of Bipolar Disorder With Clozapine Treatment: A Case Report.
Read on PubMedOne receptor, two opposite approaches: efficacy and tolerability of GIPR agonism and antagonism in obesity pharmacotherapy.
Recent research on Tirzepatide: One receptor, two opposite approaches: efficacy and tolerability of GIPR agonism and antagonism in obesity pharmacotherapy.
Read on PubMedObese and overweight patients with type 2 diabetes mellitus are not treated optimally - is it time to reconsider clinical practice?
Recent research on Tirzepatide: Obese and overweight patients with type 2 diabetes mellitus are not treated optimally - is it time to reconsider clinical practice?
Read on PubMedRelated Research
Purchase Tirzepatide from Verified Peptides
High-purity research peptides with full analytical verification
- 99% Purity (HPLC Verified)
- Full Certificate of Analysis
- Same Day Dispatch
- Free UK Shipping Over £75
Research Disclaimer
The research articles and studies referenced on this page are for informational purposes only. All products are sold for research use only and are not intended for human or animal consumption. The information provided does not constitute medical advice, diagnosis, or treatment. Always consult with qualified healthcare professionals before making any decisions related to health or medical treatment.